Lilly reports average losses of 19.5% to 20.9% at 80 weeks versus 9.4% on Ozempic 2 mg, with A1C down 2.2% against 1.8%. Dropouts from side effects ran higher on retatrutide.
Recap by typeshit. Full story at PR Newswire.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
Highlights include a real-world comparison of Wegovy 2.4 mg against resmetirom in MASH and ESSENCE data in people with a BMI under 27, presented Nov. 5 to 9 in Denver.
An investing platform's company history runs from Lilly's 1876 founding through Humulin and Prozac to its obesity drug boom. Background, not news.
Loading…